Search Results

5 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 54

    Clinical biomarkers of compliance for use in potentially reduced-risk product switching studies

    McEWAN M.(1); GALE N.(1); HARDIE G.(1); SCHERER M.(2); PLUYM N.(2); EBAJEMITO J.K.(1); CAMACHO O.M.(1); GRIFFITHS A.(1); PROCTOR C.J.(1)
    (1) British American Tobacco (Investments) Limited, Research and Development, Southampton, U.K.; (2) ABF GmbH, Planegg, Germany
    Preclinical assessments and clinical studies have shown significant reductions in toxicants in tobacco heating product (THP) aerosols compared to smoke from conventional cigarettes. Further studies to assess if these toxicant reductions translate to...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 53

    Nicotine kinetics and subjective effects of two tobacco heating products compared to cigarettes and a nicotine replacement therapy

    HARDIE G.; GALE N.; McEWAN M.; EBAJEMITO J.K.; MURPHY J.; PROCTOR C.J.
    British American Tobacco (Investments) Limited, Research and Development, Southampton, U.K.
    Recently, clinical studies have shown reductions in exposure to tobacco smoke toxicants when smokers of conventional cigarettes switch to a tobacco heating product (THP). Studies on nicotine pharmacokinetics (PK) and subjective effects of potentially...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups (Workshop), STW 08

    Biomarker qualification using adverse outcome pathways (AOPs)

    McEWAN M.; LOWE F.; GACA M.; HARDIE G.; MURPHY J.; PROCTOR C.J.
    British American Tobacco (Investments) Limited, R&D, Southampton, U.K.
    Smoking is a leading cause of numerous human disorders including pulmonary disease, cardiovascular disease and cancer. Disease development is primarily caused by years of exposure to cigarette smoke constituents, many of which are known toxicants....
  4. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 17

    A clinical study investigating changes in exposure to cigarette smoke chemicals in U.K. smokers who switch to using a tobacco heating product for a five-day period

    McEWAN M.(1); EBAJEMITO J.K.(1); GALE N.(1); ELDRIDGE A.(1); CAMACHO O.M.(1); MURPHY J.(1); HARDIE G.(1); PROCTOR C.J.(1)
    (1) British American Tobacco (Investments) Limited, R&D, Southampton, U.K.; (2) Celerion Inc., Lincoln, NE, U.S.A.
    Smoking is a leading cause of numerous diseases, particularly lung cancer, chronic obstructive pulmonary disease and cardiovascular diseases. Consequently, there is a recognized need to provide smokers with alternative nicotine-delivery devices that...
  5. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 55

    A randomised, controlled study to evaluate the effects of switching from cigarette smoking to using tobacco heating products on health effect indicators in healthy subjects

    HARDIE G.; NEWLAND N.; McEWAN M.; EBAJEMITO J.K.; GALE N.; CAMACHO O.M.; MURPHY J.; PROCTOR C.J.
    British American Tobacco (Investments) Limited, R&D, Southampton, U.K.
    Preclinical assessments and 5-day exposure clinical studies have shown that toxicant emissions are lower in tobacco heating products (THPs) compared to conventional cigarettes. However, it is unclear if these reductions are sustained and if they...